Itradora SB 65 Capsule contains Itraconazole 65 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itradora SB 65 is effective against a wide range of fungal pathogens, including dermatophytes, yeasts such as Candida species, and molds like Aspergillus species. It is commonly prescribed for the management of onychomycosis, tinea infections, blastomycosis, histoplasmosis, and other systemic and superficial mycoses. The capsule formulation ensures adequate bioavailability when administered orally, with absorption enhanced in an acidic gastric environment. Itraconazole is metabolized primarily by the liver via the cytochrome P450 system and has a relatively long half-life, allowing for convenient dosing schedules. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to its effect on CYP3A4 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and rash. Itradora SB 65 should be used under medical supervision with appropriate monitoring.